C84.32 Lymphoepithelioid lymphoma, intrathoracic lymph nodes

Name of the Condition

• Lymphoepithelioid lymphoma, intrathoracic lymph nodes (ICD-10 Code: C84.32)

Summary

Lymphoepithelioid lymphoma, intrathoracic lymph nodes, is a rare subtype of mature T-cell lymphoma characterized by a distinctive histological pattern of epithelioid histiocytes and small lymphocytes. It typically presents as localized lymphadenopathy in intrathoracic lymph nodes and may involve extranodal sites. The condition is part of the broader category of peripheral T-cell lymphomas and is distinguished by its unique cellular composition, though its clinical behavior can vary.

Causes

The exact cause of lymphoepithelioid lymphoma is not fully understood. It is believed to involve genetic alterations in T-lymphocytes, leading to abnormal proliferation and tissue infiltration. Chronic antigen stimulation or immune dysregulation may contribute to its development, though specific triggers remain unclear. No consistent association with viral infections has been established.

Risk Factors

• Age: More common in adults, particularly those over 50.
• Immunosuppression: Conditions or treatments that weaken the immune system may increase risk.
• Genetic predisposition: Family history of lymphoma or related disorders.
• Ethnicity: Some studies suggest higher prevalence in certain populations, though data is limited.

Symptoms

• Painless swelling of intrathoracic lymph nodes.
• Potential respiratory symptoms if lymph nodes compress nearby structures.
• Systemic symptoms (e.g., fever, night sweats, weight loss) may occur in advanced cases.

Diagnosis

Diagnosis involves a combination of clinical evaluation, imaging (e.g., CT or PET scans) to assess lymph node involvement, and histopathological examination of tissue samples. Biopsy is essential to confirm the characteristic epithelioid histiocyte and lymphocyte pattern. Immunophenotyping and molecular studies may be used to rule out other lymphoma subtypes and assess for genetic markers.

Treatment Options

Treatment depends on disease stage, symptoms, and patient health. Options may include chemotherapy, targeted therapy, or radiation for localized disease. Clinical trials or novel therapies may be considered for refractory cases. Multidisciplinary care involving hematologists and oncologists is typical.

Prognosis and Follow-Up

Prognosis varies based on disease extent and response to treatment. Regular follow-up with imaging and clinical assessments is important to monitor for recurrence or progression. Long-term surveillance may be recommended, especially in cases with residual disease.

Complications

• Lymph node enlargement causing organ compression (e.g., airway or vascular).
• Systemic symptoms impacting quality of life.
• Potential transformation to a more aggressive lymphoma subtype.

Lifestyle & Prevention

No specific preventive measures are known. Maintaining overall health and immune function may support general well-being. Avoiding known immunosuppressive exposures (e.g., unnecessary medications) is advisable when possible.

When to Seek Professional Help

Seek medical attention for persistent lymph node swelling, unexplained respiratory symptoms, or systemic signs like fever/weight loss. Prompt evaluation is important for early diagnosis and management.

Tips for Medical Coders

Code C84.32 is specific to lymphoepithelioid lymphoma involving intrathoracic lymph nodes. Documentation should specify the anatomical site (e.g., mediastinal, hilar) and confirm the histological subtype. Ensure alignment with ICD-10-CM guidelines for lymphoma coding, including proper sequencing if multiple sites are involved.